Bronchiectasis
Stories
-
Boehringer Ingelheim registers Phase 3 study of verducatib in bronchiectasis
The study, NCT07915219, plans to enroll 1500 participants and begin on January 11, 2027, to evaluate long-term safety and efficacy of verducatib in patients with bronchiectasis. Participants can stay in the study for up to 1 year and 9 months, with primary completion projected for July 31, 2029.